Antischistosomal activity of acridanone- hydrazones in Cebus monkeys experimentally infected with the SJ strain of Schistosoma mansoni

Abstract

In this study, four compounds were utilized at the dose of 12.5 mg/kg body weight, p.o., to treat Cebus monkeys experimentally infected with about 200 cercariae of Schistosoma mansoni (SJ strain), via transcutaneous route. The oograms performed with rectal snips, as well as stool examinations carried out periodically, showed no viable eggs of the parasite, from day 29 to 226 post-treatment. The perfusion undertaken after killing the animals showed absence of worms in the treated monkeys, whereas 83 worms were recovered from the control, thus corroborating the results obtained by means of oograms and coproscopy. These results confirm the efficacy of 9-acridanone-hydrazones previously tested against the LE strain of S. mansoni. The low curative dose and apparent absence of toxicity render these drugs an important therapeutic reserve, taking into consideration the reports on the resistance of S. mansoni to the modern drugs oxamniquine and praziquantel.

Synthesis, characterization, and BSA binding studies of newfangled 2-phenylacetohydrazide derivatives

“…In the post-modern era, numerous efforts are being made by scientists in the development of new compounds with improved efficacy and reduced toxicity, to be considered for pharmaceutical applications. Hydrazones have inspired chemists because of their diverse biological properties such as antimycobacterial [ 1 ] anticonvulsant [ 2 ], analgesic, anti-inflammatory, antiplatelet aggregation [ 3 ], antischistosomal [ 4 ], antiviral [ 5 ], anti-malarial [ 6 ], antimicrobial [ 7 ], antihypertensive [ 8 ] antitrypanosomal [ 9 ] and epidermal growth factor receptor (EGFR) inhibitory [ 10 ].…”